Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.16
CELG's Cash-to-Debt is ranked lower than
95% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CELG: 0.16 )
Ranked among companies with meaningful Cash-to-Debt only.
CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 3.45 Max: No Debt
Current: 0.16
0.03
No Debt
Equity-to-Asset 0.10
CELG's Equity-to-Asset is ranked lower than
91% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CELG: 0.10 )
Ranked among companies with meaningful Equity-to-Asset only.
CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.73 Max: 0.98
Current: 0.1
-0.68
0.98
Debt-to-Equity 6.20
CELG's Debt-to-Equity is ranked lower than
99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. CELG: 6.20 )
Ranked among companies with meaningful Debt-to-Equity only.
CELG' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.28  Med: 0.54 Max: 6.2
Current: 6.2
-4.28
6.2
Debt-to-EBITDA 3.79
CELG's Debt-to-EBITDA is ranked lower than
72% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. CELG: 3.79 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CELG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.97  Med: 2.31 Max: 5.18
Current: 3.79
0.97
5.18
Interest Coverage 4.27
CELG's Interest Coverage is ranked lower than
92% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 4.27 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 4.27  Med: 25.97 Max: 428.04
Current: 4.27
4.27
428.04
Piotroski F-Score: 6
Altman Z-Score: 2.92
Beneish M-Score: -2.65
WACC vs ROIC
9.37%
10.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 18.95
CELG's Operating Margin % is ranked higher than
87% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CELG: 18.95 )
Ranked among companies with meaningful Operating Margin % only.
CELG' s Operating Margin % Range Over the Past 10 Years
Min: 12.23  Med: 28.57 Max: 34.78
Current: 18.95
12.23
34.78
Net Margin % 19.81
CELG's Net Margin % is ranked higher than
90% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CELG: 19.81 )
Ranked among companies with meaningful Net Margin % only.
CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.45 Max: 28.88
Current: 19.81
-68.02
28.88
ROE % 41.37
CELG's ROE % is ranked higher than
97% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CELG: 41.37 )
Ranked among companies with meaningful ROE % only.
CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 25.73 Max: 43.49
Current: 41.37
-48.42
43.49
ROA % 8.73
CELG's ROA % is ranked higher than
90% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CELG: 8.73 )
Ranked among companies with meaningful ROA % only.
CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 8.73
-38.07
15.8
ROC (Joel Greenblatt) % 380.12
CELG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CELG: 380.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 408.45
Current: 380.12
-421.4
408.45
3-Year Revenue Growth Rate 20.60
CELG's 3-Year Revenue Growth Rate is ranked higher than
77% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CELG: 20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: 31 Max: 241.3
Current: 20.6
-42.8
241.3
3-Year EBITDA Growth Rate 24.10
CELG's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CELG: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.3 Max: 173.3
Current: 24.1
0
173.3
3-Year EPS without NRI Growth Rate 15.10
CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CELG: 15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.5 Max: 109.7
Current: 15.1
0
109.7
GuruFocus has detected 3 Warning Signs with Celgene Corp CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CELG's 30-Y Financials

Financials (Next Earnings Date: 2018-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

CELG Guru Trades in Q3 2017

Frank Sands 4,130 sh (New)
Stanley Druckenmiller 188,100 sh (New)
Steven Cohen 77,242 sh (New)
Ray Dalio 85,286 sh (+109.03%)
Joel Greenblatt 195,353 sh (+15.72%)
Signature Select Canadian Fund 51,850 sh (+0.78%)
Ken Fisher 265,695 sh (+0.67%)
Ronald Muhlenkamp 3,000 sh (unchged)
Lee Ainslie Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 71,455 sh (-1.33%)
Mario Gabelli 10,250 sh (-2.65%)
Murray Stahl 7,939 sh (-2.65%)
Jeremy Grantham 2,700 sh (-10.00%)
David Rolfe 676,776 sh (-15.34%)
Julian Robertson 219,540 sh (-22.49%)
Pioneer Investments 2,522,142 sh (-51.44%)
Jim Simons 410,238 sh (-64.96%)
Eaton Vance Worldwide Health Sciences Fund 409,520 sh (-7.96%)
» More
Q4 2017

CELG Guru Trades in Q4 2017

Richard Pzena 2,371 sh (New)
First Pacific Advisors 4,175 sh (New)
Tom Russo 500 sh (New)
Frank Sands 43,919 sh (+963.41%)
Ray Dalio 290,776 sh (+240.94%)
Steven Cohen 200,000 sh (+158.93%)
Jim Simons 796,200 sh (+94.08%)
David Rolfe 962,318 sh (+42.19%)
Joel Greenblatt 200,934 sh (+2.86%)
Ronald Muhlenkamp 3,000 sh (unchged)
Julian Robertson Sold Out
Jeremy Grantham Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl 7,900 sh (-0.49%)
Ronald Muhlenkamp 70,101 sh (-1.89%)
Ken Fisher 231,106 sh (-13.02%)
Mario Gabelli 3,400 sh (-66.83%)
Pioneer Investments 814,675 sh (-67.70%)
Eaton Vance Worldwide Health Sciences Fund 386,544 sh (-5.61%)
» More
Q1 2018

CELG Guru Trades in Q1 2018

Scott Black 20,260 sh (New)
Paul Tudor Jones 68,005 sh (New)
Mairs and Power 3,030 sh (New)
Jim Simons 2,570,838 sh (+222.89%)
Richard Pzena 4,825 sh (+103.50%)
Joel Greenblatt 388,970 sh (+93.58%)
Ray Dalio 452,364 sh (+55.57%)
Frank Sands 65,744 sh (+49.69%)
Ken Fisher 309,343 sh (+33.85%)
Pioneer Investments 851,304 sh (+4.50%)
Ronald Muhlenkamp 72,493 sh (+3.41%)
Steven Cohen 100,000 sh (unchged)
Tom Russo Sold Out
First Pacific Advisors Sold Out
Signature Select Canadian Fund Sold Out
David Rolfe 924,542 sh (-3.93%)
Mario Gabelli 3,100 sh (-8.82%)
Murray Stahl 7,000 sh (-11.39%)
Steven Cohen 96,800 sh (-51.60%)
Eaton Vance Worldwide Health Sciences Fund 274,651 sh (-28.95%)
» More
Q2 2018

CELG Guru Trades in Q2 2018

Paul Tudor Jones 172,031 sh (+152.97%)
Jim Simons 4,129,438 sh (+60.63%)
Joel Greenblatt 565,173 sh (+45.30%)
Ray Dalio 546,369 sh (+20.78%)
Ken Fisher 322,086 sh (+4.12%)
Pioneer Investments 874,432 sh (+2.72%)
Murray Stahl 7,030 sh (+0.43%)
Ronald Muhlenkamp 72,493 sh (unchged)
Steven Cohen Sold Out
Frank Sands Sold Out
Mairs and Power 2,980 sh (-1.65%)
Mario Gabelli 3,000 sh (-3.23%)
Richard Pzena 4,518 sh (-6.36%)
David Rolfe 864,236 sh (-6.52%)
Eaton Vance Worldwide Health Sciences Fund 225,793 sh (-17.79%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-06-30 Add 45.30%0.2%$74.69 - $92.08 $ 90.379%565,173
Ken Fisher 2018-06-30 Add 4.12%$74.69 - $92.08 $ 90.379%322,086
Richard Pzena 2018-06-30 Reduce -6.36%$74.69 - $92.08 $ 90.379%4,518
Mario Gabelli 2018-06-30 Reduce -3.23%$74.69 - $92.08 $ 90.379%3,000
Joel Greenblatt 2018-03-31 Add 93.58%0.24%$84.98 - $109.14 $ 90.37-6%388,970
Ken Fisher 2018-03-31 Add 33.85%0.01%$84.98 - $109.14 $ 90.37-6%309,343
Ronald Muhlenkamp 2018-03-31 Add 3.41%0.08%$84.98 - $109.14 $ 90.37-6%72,493
Richard Pzena 2018-03-31 Add 103.50%$84.98 - $109.14 $ 90.37-6%4,825
Mario Gabelli 2018-03-31 Reduce -8.82%$84.98 - $109.14 $ 90.37-6%3,100
Ken Fisher 2017-12-31 Reduce -13.02%0.01%$98.17 - $146.52 $ 90.37-20%231,106
Joel Greenblatt 2017-12-31 Add 2.86%0.01%$98.17 - $146.52 $ 90.37-20%200,934
Ronald Muhlenkamp 2017-12-31 Reduce -1.89%0.06%$98.17 - $146.52 $ 90.37-20%70,101
Mario Gabelli 2017-12-31 Reduce -66.83%0.01%$98.17 - $146.52 $ 90.37-20%3,400
Richard Pzena 2017-12-31 New Buy$98.17 - $146.52 $ 90.37-20%2,371
Julian Robertson 2017-12-31 Sold Out 5.79%$98.17 - $146.52 $ 90.37-20%0
Ken Fisher 2017-09-30 Add 0.67%$127.43 - $144.94 $ 90.37-34%265,695
Julian Robertson 2017-09-30 Reduce -22.49%1.63%$127.43 - $144.94 $ 90.37-34%219,540
Joel Greenblatt 2017-09-30 Add 15.72%0.06%$127.43 - $144.94 $ 90.37-34%195,353
Ronald Muhlenkamp 2017-09-30 Reduce -1.33%0.04%$127.43 - $144.94 $ 90.37-34%71,455
Mario Gabelli 2017-09-30 Reduce -2.65%$127.43 - $144.94 $ 90.37-34%10,250
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ASX:CSL, NAS:BIIB, LSE:SHP, NAS:GILD, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:ALXN, OCSE:NOVO B, NAS:AMGN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV » details
Traded in other countries:CELG.Austria, CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Guru Investment Theses on Celgene Corp

David Rolfe Comments on Celgene - Jul 13, 2018

Celgene (NASDAQ:CELG) was once again a top detractor during the quarter. We chronicled the recent pipeline disappointments and earnings guidance declines in our third quarter Client Letter back in October. We recognize that the Company needs to regain investor confidence. To that end, we continue to reiterate that the Company has a very broad pipeline, with 12 phase-III studies set to read out between now and the end of 2018. Celgene has substantially more phase III assets than any other biotech company. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity.

From David Rolfe (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Celgene - Jan 12, 2018

Celgene (NASDAQ:CELG)



Celgene was a top detractor to performance due to a couple negative news events released during the quarter. The company announced they would discontinue a phase III trial for their drug GED-0301 in Crohn's disease (CD) and an extension trial, following a recommendation of the Data Monitoring Committee. They also decided that another phase 1 trial for Crohn's disease would not be initiated. While a phase II trial with GED-0301 in ulcerative colitis is still ongoing, the Company is currently awaiting review of data to determine their next steps for this indication. In the absence of any information on whether the trial failure was due to something specific to CD or the drug itself, it is currently assumed to be a high-risk program for that indication. This study was deemed a high risk/low-probability study, especially when compared to other IBD drugs. However, its success could have been a blockbuster Inflammation & Immunology (I&I) asset for the company, making its failure a disappointing loss.



In addition to these trial failures, during the third quarter earnings release, management brought down 2020 guidance, partially due to the discontinuation of GED-0301 program in CD. While sales were only modest in their 2020 model, management did forecast multibillion dollar peak sales potential for the drug. The largest impact to 2020 guidance, however, was weak performance of their existing drug Otezla, which experienced headwinds due to slowing growth and increased competition in the psoriatic arthritis and psoriasis markets. The updated guidance takes into account GED-0301, the market dynamics impacting Otezla, as well as reassesses the opportunities and risks associated with the remaining phase III studies expected to read out by the end of 2018. We believe management took a conservative stance with their update and yet the resulting guide maintains more than +14% revenue growth and nearly +20% earnings growth on a compounded annual basis through 2020.



We realize there will be phase III failures; and with each failure comes the potential for more risk and less growth. We reiterate that the Company has a very broad pipeline, with 12 phase 1 studies set to read out between now and the end of this year, making setbacks like these more manageable in the longer term. Celgene has substantially more phase III assets than any other biotech company. Several of these pipeline assets are not incorporated in the current 2020 guidance, as they read out at a date when any sales potential will contribute at future dates. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity.

From David Rolfe (Trades, Portfolio)'s fourth quarter 2017 shareholder commentary.

Check out David Rolfe latest stock trades

Spiros Segalas Commentary on Celgene - Jul 10, 2017

Celgene (NASDAQ:CELG) rose on positive results from a trial of an experimental compound to treat relapsed/refractory multiple myeloma. We consider Celgene, with its robust revenue and earnings, and deep pipeline, one of the biotechnology sector’s most fundamentally sound companies. As of the end of the period, the Fund focused its holdings in high-conviction biotechnology and specialty pharmaceutical companies. We expect that productive research and development activity will yield effective disease treatments that improve the quality of patients’ lives, characteristics that historically have been the source of longer-term outperformance in the sector.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Top Ranked Articles about Celgene Corp

Weekly Top Insider Buys Highlight for the Week of Aug. 10 The largest insider buys this week were for AT&T Inc. (T), Celgene Corp. (CELG), Crown Castle International Corp. (CCI) and Marriott International Inc. (MAR)
The largest Insider Buys this week were for AT&T Inc. (NYSE:T), Celgene Corp. (NASDAQ:CELG), Crown Castle International Corp. (NYSE:CCI), and Marriott International Inc. (NASDAQ:MAR). Read more...
Risk-Reward With Jim Simons Bargain Stock Celgene Down 20% year to date and Simons keeps buying
Jim Simons (Trades, Portfolio)’ Rennessaince Technologies owns a multitude of stocks. Celgene Corp (NASDAQ:CELG) is just another in a long list. Renaissance Technologies owns 2,570,838 million shares, good for 0.25% of the firm's public equity portfolio, but it probably deserves a larger position in your portfolio. Read more...
David Rolfe Comments on Celgene Guru stock highlight
Celgene (NASDAQ:CELG) was once again a top detractor during the quarter. We chronicled the recent pipeline disappointments and earnings guidance declines in our third quarter Client Letter back in October. We recognize that the Company needs to regain investor confidence. To that end, we continue to reiterate that the Company has a very broad pipeline, with 12 phase-III studies set to read out between now and the end of 2018. Celgene has substantially more phase III assets than any other biotech company. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity. Read more...
Global Capital Markets High on Friday Nike shares jumps on earnings report
The U.S. stock market jumped today in morning trading, with the Dow Jones Industrial Average rallying 250 points. Read more...
Report: Developing Opportunities within Equinix, Sonus Networks, Celgene, National Grid, Atlas Air Worldwide, and Copa Holdings, S.A. — Future Expectations, Projections Moving into 2018
2 Biotech Stocks Move Monday Nektar Therapeutics falls, Bluebird Bio rises
In Monday trading, shares of Nektar Therapeutics Inc. (NASDAQ:NKTR) plummeted after announcing the results of preliminary data from a phase 1/2 clinical trial, called PIVOT, which assesses the combination of NKTR-214 and Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in a range of cancers. The results were presented at the American Society of Clinical Oncology (ASCO) in Chicago. Read more...
DEADLINE TODAY: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)
CELGENE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Celgene Corporation To Contact The Firm
CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018
FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq:CELG) To Contact The Firm

Ratios

vs
industry
vs
history
PE Ratio 24.83
CELG's PE Ratio is ranked higher than
54% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. CELG: 24.83 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 39.65 Max: 176.19
Current: 24.83
17.92
176.19
Forward PE Ratio 10.47
CELG's Forward PE Ratio is ranked higher than
90% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. CELG: 10.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.83
CELG's PE Ratio without NRI is ranked higher than
54% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. CELG: 24.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.92  Med: 39.65 Max: 176.19
Current: 24.83
17.92
176.19
Price-to-Owner-Earnings 19.85
CELG's Price-to-Owner-Earnings is ranked higher than
71% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. CELG: 19.85 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.43  Med: 35.58 Max: 569.6
Current: 19.85
15.43
569.6
PB Ratio 18.51
CELG's PB Ratio is ranked lower than
92% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CELG: 18.51 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.29 Max: 18.68
Current: 18.51
4.02
18.68
PS Ratio 4.97
CELG's PS Ratio is ranked higher than
70% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 4.97 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 4.29  Med: 8.9 Max: 25.05
Current: 4.97
4.29
25.05
Price-to-Free-Cash-Flow 21.01
CELG's Price-to-Free-Cash-Flow is ranked higher than
66% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. CELG: 21.01 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.86  Med: 28.35 Max: 252.23
Current: 21.01
14.86
252.23
Price-to-Operating-Cash-Flow 19.19
CELG's Price-to-Operating-Cash-Flow is ranked higher than
67% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. CELG: 19.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.85  Med: 26.2 Max: 143.4
Current: 19.19
13.85
143.4
EV-to-EBIT 16.00
CELG's EV-to-EBIT is ranked higher than
61% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CELG: 16.00 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.2  Med: 29 Max: 86.1
Current: 16
-30.2
86.1
EV-to-EBITDA 14.51
CELG's EV-to-EBITDA is ranked higher than
60% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CELG: 14.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -34  Med: 24.9 Max: 79.5
Current: 14.51
-34
79.5
EV-to-Revenue 5.77
CELG's EV-to-Revenue is ranked higher than
70% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CELG: 5.77 )
Ranked among companies with meaningful EV-to-Revenue only.
CELG' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.1  Med: 9 Max: 23.6
Current: 5.77
5.1
23.6
PEG Ratio 1.16
CELG's PEG Ratio is ranked higher than
63% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. CELG: 1.16 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.21 Max: 3.26
Current: 1.16
0.91
3.26
Shiller PE Ratio 43.52
CELG's Shiller PE Ratio is ranked lower than
51% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. CELG: 43.52 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 37.54  Med: 134.93 Max: 3102
Current: 43.52
37.54
3102
Current Ratio 1.52
CELG's Current Ratio is ranked lower than
83% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CELG: 1.52 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 7.01 Max: 44.53
Current: 1.52
1.35
44.53
Quick Ratio 1.40
CELG's Quick Ratio is ranked lower than
79% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CELG: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.82 Max: 44.15
Current: 1.4
1.13
44.15
Days Inventory 396.08
CELG's Days Inventory is ranked lower than
91% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. CELG: 396.08 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 105.47  Med: 297.82 Max: 411.32
Current: 396.08
105.47
411.32
Days Sales Outstanding 53.35
CELG's Days Sales Outstanding is ranked higher than
61% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. CELG: 53.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.55  Med: 57.78 Max: 71.27
Current: 53.35
50.55
71.27
Days Payable 215.48
CELG's Days Payable is ranked higher than
79% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. CELG: 215.48 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 172.59 Max: 241.49
Current: 215.48
61.81
241.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CELG: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.1  Med: -5.3 Max: 4.5
Current: 1.7
-25.1
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.41
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. CELG: 1.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.24  Med: 4.17 Max: 124
Current: 1.41
1.24
124
Price-to-Median-PS-Value 0.56
CELG's Price-to-Median-PS-Value is ranked higher than
74% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CELG: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.9 Max: 30
Current: 0.56
0.49
30
Price-to-Peter-Lynch-Fair-Value 1.05
CELG's Price-to-Peter-Lynch-Fair-Value is ranked higher than
69% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. CELG: 1.05 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.78 Max: 5.1
Current: 1.05
0.36
5.1
Earnings Yield (Greenblatt) % 6.24
CELG's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CELG: 6.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.5  Med: 3 Max: 6.8
Current: 6.24
-7.5
6.8
Forward Rate of Return (Yacktman) % 24.30
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
92% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. CELG: 24.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.3  Med: 2.6 Max: 25
Current: 24.3
0.3
25

More Statistics

Revenue (TTM) (Mil) $14,122.00
EPS (TTM) $ 3.64
Beta1.35
Volatility38.97%
52-Week Range $74.13 - 147.17
Shares Outstanding (Mil)703.36

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 15,084 17,005 19,477
EBIT (Mil $) 6,236 8,692 10,761
EBITDA (Mil $) 6,952 9,077 10,997
EPS ($) 6.47 8.92 11.04
EPS without NRI ($) 6.47 8.92 11.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
19.93%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}